Dover has entered right into a definitive agreement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and management devices for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will expand Dover’s biopharma single-use manufacturing offering, which already consists of Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue in the course of the full year 2022.
When Dollar closes, Malema will turn into a part of the PSG enterprise unit within Dover’s Pumps & Process Solutions section.
“We see an incredible long-term progress alternative within the bioprocessing business driven by a strong and growing pipeline of effective novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra efficient single-use production processes helps a robust outlook for our choices of single-use elements to end-customers. We believe that pairing Malema’s know-how with our present portfolio of single-use pumps for biopharma processing will tremendously enhance the accuracy and worth proposition of our options to our clients.”
“We are methodically constructing out our biopharma platform via proactive capacity additions, new product growth, and opportunistic acquisitions of highly-attractive area of interest element technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary technology. In Best selling to attractive biopharma purposes, we count on strong development in the semiconductor space on the capacity expansion and re-shoring tailwinds.”
Shareg